Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.75B P/E - EPS this Y 240.50% Ern Qtrly Grth 2,897.20%
Income 30.57M Forward P/E 45.63 EPS next Y 59.60% 50D Avg Chg 12.00%
Sales 890.53M PEG -0.08 EPS past 5Y - 200D Avg Chg 45.00%
Dividend N/A Price/Book 12.06 EPS next 5Y -357.00% 52W High Chg -14.00%
Recommedations 2.20 Quick Ratio 1.81 Shares Outstanding 165.88M 52W Low Chg 113.00%
Insider Own 0.54% ROA 1.83% Shares Float 108.46M Beta 0.39
Inst Own 99.95% ROE 6.70% Shares Shorted/Prior 9.23M/10.66M Price 29.20
Gross Margin 51.34% Profit Margin 3.43% Avg. Volume 1,634,129 Target Price 25.28
Oper. Margin 12.58% Earnings Date Oct 31 Volume 1,707,063 Change 0.90%
About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc. News
11/15/24 Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/13/24 High Growth Tech Stocks to Watch in November 2024
11/12/24 Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
11/09/24 ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next
11/08/24 ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations
11/07/24 ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...
11/06/24 Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates
11/06/24 Acadia: Q3 Earnings Snapshot
11/06/24 Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
11/05/24 Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
10/31/24 ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024
05:41 PM Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
06:28 AM Health Canada approves Acadia’s DAYBUE for Rett syndrome
10/16/24 Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
10/14/24 Are ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
09/23/24 Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
09/03/24 High Growth Tech Stocks To Watch In September 2024
08/29/24 Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
08/28/24 Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
08/14/24 Ryan Reynolds Announces More to Parkinson’s® Campaign
ACAD Chatroom

User Image DownsideKing Posted - 9 hours ago

$ACAD Kamala Harris’s campaign had more legs than this POS stock!! Over $50 a share 8 years ago to sitting $15 for the last 8. Zeus and his boy Ritchie aka Tootzsoon will be still waiting for a move up 10 years from now. This stock with or without Steve Davis is hopeless!! No pipeline and 2 dead drugs!

User Image Ham1198 Posted - 16 hours ago

$ACAD more inducement grants yesterday. What else is new

User Image BioRich Posted - 19 hours ago

@USMAgrad @smelter I love that pick. I got $ACAD around the same time (kept getting the ticker mixed up, researched both and both were winners). Check out $APLS too. Came across my plate a few weeks ago and immediately went into the "pound the table" must buy category. Worth a look. Let's make some money. Cheers!

User Image DownsideKing Posted - 1 day ago

$ACAD this stock will Forever be the disaster of the industry What a POS!

User Image Ham1198 Posted - 1 day ago

$ACAD only down 10% for the week. Not bad

User Image DownsideKing Posted - 1 day ago

$ACAD

User Image DownsideKing Posted - 1 day ago

$ACAD down to $12 we go!! Here we come Zeusy!!!

User Image UncleTonyTootszoon Posted - 1 day ago

$ACAD Grazie a Dio è venerdì posso usare il mio assegno sociale per comprare un po' di più di questa merda. Alla fine salirà o scenderà nel gabinetto come una grande vecchia merda

User Image DownsideKing Posted - 2 days ago

$ACAD on the way to $12 Richie Tootsoon is about to lose his braciole!

User Image Ham1198 Posted - 2 days ago

$ACAD KISS all those gains goodbye

User Image UncleTonyTootszoon Posted - 2 days ago

$ACAD downside è proprio un cagacazzo.Non dire cazzate!Rottinculo lmao

User Image BobBijawklah Posted - 2 days ago

$ACAD The Ryan Reynolds campaign will surely bring 15% of new nuplazid scripts. Canada about the same for dayblue. So we should see a nice bump in earning and revenue. On top of that new CEO is a pro at super charging sales force . So 1.2 billion to 1.5 billion is my probable 2025 revenue mark price target 25. Sorry downside your target is hopeless

User Image DownsideKing Posted - 3 days ago

$ACAD $12

User Image kenbkb Posted - 3 days ago

$ZETA I can vouch for this list. All of these stocks attacked by Culper with these two exceptions, $ACAD and $GCT, are doing well. All the rest of the stocks/companies seem to have weathered the storm and are doing fine.

User Image kenbkb Posted - 3 days ago

@iSmith Wait a minute, so did $ACAD. It went lower and it kept going lower. Where are you showing that these company's rebounded? I only see that with $KSPI.

User Image DownsideKing Posted - 3 days ago

$ACAD Tootszoon is a real strunz!

User Image DownsideKing Posted - 3 days ago

$ACAD I like Ritchie’s new name Tootszoon! Questo pezzo di merda pensa di Ingannare tutte! Via a fanculo tua madra!

User Image UncleTonyTootszoon Posted - 3 days ago

$ACAD Downsider ha una salsiccia molto piccola che gli piace infilare nella parte posteriore del suo ragazzo. See you at 30 Mr stunad.

User Image DownsideKing Posted - 3 days ago

$ACAD uncle tootsie about to lose his culo today!!! Here come the next stop at $16 on the way to $12! Vaffanculo Tori!!!

User Image DownsideKing Posted - 4 days ago

$ACAD don’t worry knob I’m sure some weak minded individual will report me soon.

User Image BobBijawklah Posted - 4 days ago

$ACAD i see downside has a new boyfriend . Uncle tootsoon .

User Image DownsideKing Posted - 4 days ago

$ACAD listen you Tootszoon succhiacazzi! You haven’t been paying attention long! This pezzo di merda is going to $12! I’ll bet your little cannoli on it!

User Image UncleTonyTootszoon Posted - 4 days ago

$ACAD a fanabala fica downside 30 is coming by end of february

User Image DownsideKing Posted - 4 days ago

$ACAD )12

User Image HorizonBull Posted - 4 days ago

$ACAD added 1k

User Image UncleTonyTootszoon Posted - 4 days ago

$ACAD You have to have conviction to add and hold for the reward is in the bucket

User Image BobBijawklah Posted - 4 days ago

$ACAD downsider lives in his moms basement eating cheese puffs and watching porn .

User Image UncleTonyTootszoon Posted - 4 days ago

$ACAD PASS UNCLE TOOTSOON THE MACARONI AND CHEESE!

User Image DownsideKing Posted - 4 days ago

$ACAD time to retreat back to $12 It’s hard to repair a leaky Titanic

User Image UncleTonyTootszoon Posted - 4 days ago

$ACAD uncle tony says here comes 20 . no downside in sight . just call me Mr. kablaygoots.

Analyst Ratings
Citigroup Buy Aug 8, 24
UBS Buy Aug 8, 24
HC Wainwright & Co. Buy Aug 8, 24
Needham Buy Aug 7, 24
Cantor Fitzgerald Overweight Aug 7, 24
RBC Capital Outperform Aug 7, 24
Morgan Stanley Equal-Weight Aug 7, 24
Morgan Stanley Overweight Jul 12, 24
BMO Capital Outperform Jun 27, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DAVIS STEPHEN CEO CEO Jan 06 Sell 29.96 3,732 111,811 96,521 01/09/24
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Jan 06 Sell 29.96 731 21,901 30,949 01/09/24
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Jan 06 Sell 29.96 590 17,676 46,901 01/09/24
Kihara James Principal Accounting.. Principal Accounting Officer Dec 15 Sell 28.30 2,000 56,600 11,025 12/15/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Nov 17 Sell 22.64 4,960 112,294 30,393 11/21/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Nov 17 Sell 22.64 5,108 115,645 20,486 11/21/23
Kihara James Principal Accounting.. Principal Accounting Officer Nov 17 Sell 22.64 1,985 44,940 13,025 11/21/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Oct 05 Sell 21.96 16,369 359,463 45,857 10/06/23
DAVIS STEPHEN CEO CEO Oct 05 Sell 21.96 51,563 1,132,323 89,131 10/06/23
Kihara James Principal Accounting.. Principal Accounting Officer Sep 15 Sell 25.88 2,000 51,760 10,778 09/19/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Aug 21 Sell 28.997 10,000 289,970 15,682 08/23/23
DAVIS STEPHEN CEO CEO Jul 14 Option 20.77 100,000 2,077,000 136,695 07/18/23
DAVIS STEPHEN CEO CEO Jul 14 Sell 30.04 100,000 3,004,000 36,695 07/18/23
DAVIS STEPHEN CEO CEO Jul 11 Sell 25.03 71,602 1,792,198 36,695 07/13/23
Brege Laura Director Director Jun 12 Sell 24.868 4,500 111,906 13,502 06/14/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Sell 25.02 974 24,369 22,824 06/12/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Option 0 1,893 23,798 06/12/23
BAKER BROS. ADVISORS LP Director Director May 22 Buy 25.22 896,522 22,610,285 39,317,673 05/24/23
BAKER BROS. ADVISORS LP Director Director May 22 Option 17.01 25,000 425,250 38,620,261 05/24/23
Kihara James Principal Accounting.. Principal Accounting Officer May 17 Sell 22.5 5,947 133,808 11,144 05/19/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer May 17 Sell 22.5 15,310 344,475 21,905 05/19/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial May 17 Sell 22.5 14,869 334,552 24,356 05/19/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 29 Sell 21.18 917 19,422 25,513 05/02/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Sell 21.18 548 11,607 9,487 05/02/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Option 0 1,567 10,035 05/02/23
DAVIS STEPHEN CEO CEO Apr 29 Sell 21.18 7,806 165,331 108,297 05/02/23
DAVIS STEPHEN CEO CEO Apr 29 Option 0 15,625 116,103 05/02/23
Kihara James Principal Accounting.. Principal Accounting Officer Apr 07 Sell 18.14 523 9,487 5,197 04/11/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 05 Sell 18.16 1,751 31,798 8,468 04/07/23
Kihara James Principal Accounting.. Principal Accounting Officer Apr 05 Sell 18.16 701 12,730 4,231 04/07/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Apr 05 Sell 18.16 1,916 34,795 7,477 04/07/23
DAVIS STEPHEN CEO CEO Apr 05 Sell 18.16 8,582 155,849 100,478 04/07/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 05 Sell 18.16 1,456 26,441 23,425 04/07/23
Kihara James Principal Accounting.. Principal Accounting Officer Feb 23 Sell 18.78 350 6,573 2,923 02/27/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Feb 23 Sell 18.78 577 10,836 4,118 02/27/23
DAVIS STEPHEN CEO CEO Feb 23 Sell 18.78 3,851 72,322 91,727 02/27/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Feb 23 Sell 18.78 803 15,080 20,108 02/27/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Feb 23 Sell 18.78 461 8,658 5,195 02/27/23
BAKER BROS. ADVISORS LP Director Director Jan 12 Option 5.22 30,000 156,600 38,484,981 01/17/23
DAVIS STEPHEN CEO CEO Jan 06 Sell 17.13 3,904 66,876 84,633 01/10/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Jan 06 Sell 17.13 532 9,113 4,549 01/10/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Jan 06 Sell 17.13 589 10,090 18,697 01/10/23
Stankovic Srdjan R. President President Oct 15 Sell 15.81 1,326 20,964 56,831 10/18/22
DAVIS STEPHEN CEO CEO Oct 15 Sell 15.81 2,804 44,331 79,009 10/18/22
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Option 0 1,893 3,995 06/10/22
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Sell 17.91 653 11,695 3,342 06/10/22
DAVIS STEPHEN CEO CEO Apr 29 Sell 18.18 5,483 99,681 75,875 05/03/22
Stankovic Srdjan R. President President Apr 29 Sell 18.18 2,865 52,086 55,188 05/03/22
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 29 Sell 18.18 894 16,253 16,742 05/03/22
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Sell 18.18 552 10,035 3,437 05/03/22